Company Snapshot: Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. The company’s lead product candidate, Omadacycline, is a novel investigational antibiotic with both once-daily intravenous (IV) and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP), acute bacterial skin and skin structure infections (ABSSSI), and urinary tract infections (UTI). A modernized tetracycline, omadacycline is specifically designed to overcome tetracycline resistance and exhibits activity across a broad spectrum of bacteria, including Gram-positive, Gram-negative, anaerobes, atypical bacteria, and other drug-resistant strains.
- Jan 18 2023 Paratek Pharmaceuticals Announces Inclusion of NUZYRA® (omadacycline) in China’s National Reimbursement Drug List (NRDL)
- Jan 5 2023 Paratek Pharmaceuticals Receives $36.4 Million Milestone Payment Associated with the Second Procurement of NUZYRA® (omadacycline) under BARDA Project BioShield Contract
- Dec 20 2022 Paratek Pharmaceuticals Appoints Jeffrey Stein as Lead Independent Director of the Board
- Dec 19 2022 Paratek Pharmaceuticals Announces Positive Top Line Data from Pilot Efficacy Study for the Treatment of Pulmonary Anthrax and Acceptance of the Second Procurement of NUZYRA® (omadacycline) under BARDA Project BioShield